Off-label use of infliximab

Autor(en): Onder, M.
Salavastru, C.
Fritz, K.
Stichwörter: Antagonist; BEHCETS-DISEASE; COMBINATION; Cytokine; Dermatology; DOUBLE-BLIND; EFFICACY; FACTOR-ALPHA INHIBITOR; Inflammation; Monoclonal antibody; PATIENT; PITYRIASIS-RUBRA-PILARIS; PYODERMA-GANGRENOSUM; THERAPY; Tumor necrosis factor alpha
Erscheinungsdatum: 2013
Herausgeber: SPRINGER HEIDELBERG
Journal: HAUTARZT
Volumen: 64
Ausgabe: 10
Startseite: 757
Seitenende: 761
Zusammenfassung: 
Tumor necrosis factor alpha (TNF alpha) is a pro-inflammatory cytokine and a key mediator of inflammation. Several TNF alpha antagonists have been used therapeutically. One of them, infliximab, is a chimeric monoclonal antibody with anti-TNF alpha activity. Numerous studies have shown TNF alpha antagonists to be effective in treating psoriasis-particularly severe resistant forms-and arthritis. Additionally, several case reports and studies showing the effects of TNF alpha on new dermatologic indications have been published. The intention of this review is to summarize the new off-label uses of infliximab according to published data.
ISSN: 00178470
DOI: 10.1007/s00105-013-2596-z

Show full item record

Page view(s)

1
Last Week
0
Last month
0
checked on Feb 26, 2024

Google ScholarTM

Check

Altmetric